Low plasma Arginine level is associated with resistance to immune checkpoint inhibitors in patients with advanced cancer
Background In the era of immuno-oncology, identifying primary resistance mechanisms to immune checkpoint inhibitors remains crucial. A better understanding of these mechanisms may help to identify novel pathways that can be targeted to improve response rates, as well as biomarkers that could support the selection of patients more likely to benefit from cancer immunotherapies. Among […]
How plasma LIF predicts immune-checkpoint blockade resistance and a TLS-poor tumor microenvironment
Why IDO1 blockade lowered kynurenine but failed to improve anti-PDL1 efficacy in sarcoma
Does cabozantinib help in advanced Ewing sarcoma and osteosarcoma — and can plasma biomarkers flag who responds?
The Kynurenine Pathway as a possible resistance mechanism to immunotherapy in sarcomas
Background Sarcomas are heterogeneous malignant mesenchymal tumors known to be particularly resistant to immunotherapy. This resistance highlights the need to better understand the biological mechanisms limiting response to immune checkpoint inhibitors. We previously observed increased activity of the kynurenine pathway in the plasma of patients treated with pembrolizumab and metronomic cyclophosphamide. The kynurenine pathway is […]
Why PD-1 blockade falls short in soft-tissue sarcoma — and the macrophage/IDO1 axis behind it
